Tirzepatide
Tirzepatide is a combined GLP-1 and GIP agonist.
Tirzepatide has the same indications and precautions as Semaglutide. It often results in greater weightlloss than Semaglutide. Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, providing a synergistic effect that may enhance glycemic control and weight loss compared to semaglutide, which primarily targets the GLP-1 receptor.
Tirzepatide and semaglutide are both glucagon-like peptide-1 (GLP-1) receptor agonists used primarily for managing type 2 diabetes and promoting weight loss. However, Tirzepatide offers several advantages over semaglutide.
Clinical trials suggest that Tirzepatide may lead to more significant weight reduction than semaglutide, making it an appealing option for patients focused on weight management. Tirzepatide may result in better HbA1c reductions than semaglutide, particularly in certain populations with type 2 diabetes.
Early research suggests that Tirzepatide might offer cardiovascular benefits, although more studies are needed to confirm this.